Recombinant Proteins Market Growth, Growth Demand, Key Drivers, Forecast To 2033

The recombinant proteins market size has grown rapidly in recent years. It will grow from $2.12 billion in 2023 to $2.37 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing demand for biopharmaceuticals, rising prevalence of chronic diseases, growing aging population, government initiatives and funding, expanding applications in research and diagnostics..

The recombinant proteins market size is expected to see rapid growth in the next few years. It will grow to $3.79 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to increased adoption of personalized medicine, rapid expansion of the biotechnology sector, global efforts to address rare diseases, advancements in protein engineering techniques, emerging markets and untapped opportunities.. Major trends in the forecast period include expansion of personalized medicine, rapid growth in the biotechnology sector, demand for therapeutic proteins, emergence of novel therapeutic targets, global focus on vaccine development..

Market Overview -
Recombinant proteins refer to modified or edited proteins encoded by recombinant DNA, made up of a plasmid in which the gene of an interest target protein is cloned downstream of a promoter region. They are used to make pharmaceuticals, protein-based polymers for drug delivery, antibodies and enzymes for disease treatment, protein scaffolds for tissue engineering, and a variety of other things.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=9959&type=smp

Rising Regulatory Approvals Fuel The Growth Of Recombinant Protein Market
A rising number of regulatory approvals is expected to propel the growth of the recombinant protein market going forward. Regulatory approvals refer to any government or health authority authorization for any research involving human subjects. A rising number of regulatory approvals for recombinant proteins is mandatory for all drugs, which includes the treatment of diabetes, and severe chronic diseases like cancer, cardiovascular diseases, endocrine diseases, and viral diseases. For instance, in January 2022, according to the Centre for Drug Evaluation and Research (CDER), a US-based non-profit organization, 38 (76%) of the 50 medications CDER authorized in 2021 received their first U.S. approval. In comparison to 21 of 53 first-in-class pharmaceuticals (39.5%) in 2020, first-in-class drugs made up 27 of the 50 drugs (54%) approved in 2021, the agency observed. The FDA previously reported that 20 drugs were approved (42%), 19 were approved (32%), and 15 were approved (33%). Therefore, the rising number of regulatory approvals is driving the growth of the recombinant protein market going forward.

Competitive Landscape -
Major companies operating in the recombinant proteins market report are Abcam plc, Abnova Corporation, Bio-Rad Laboratoroies Inc., Merck Co. & KGaA, R&D Systems Inc., Proteintech Group Inc., RayBiotech Life Inc., GenScript Biotech Corporation, Elpiscience Biopharmaceuticals Co. Ltd., Elevian Inc., Gigagen Inc., Janssen- Cilag Pvt. Ltd., Sino Biological Inc., OriGene Technologies Inc., Feldan Therapeutics Inc., Randox Laboratories Ltd., Plant Biotechnology Inc., Infinite Enzymes Inc., Bio-Techne Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Crown Bioscience Inc., Airway Therapeutics Inc., Amgen Inc., Aviva Systems Biology Corp., Bracco Imaging S.p.A., Cardinal Health Inc., Eli Lilly and Company, Gamma Medica Inc., LambdaSpect Ltd. .

Innovative Product Developments Driving Recombinant Protein Market Growth
Product innovation is the key trend gaining popularity in the recombinant protein market. Major companies operating in the recombinant protein market are focused on developing innovative products to strengthen their position in the market. For instance, in March 2022, ProteoGenix, a France-based biochemistry company launched the XtenCHO Transient CHO Expression System, aimed at improving biologics development. This new system offers several advantages, including ten times higher yields, optimized plasmid stability, and smart protocols with less hands-on time. The XtenCHO™system is designed to be a rapid and cost-effective solution, ideal for both bioanalytical applications and drug development.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/recombinant-proteins-global-market-report

Key Segments -

The recombinant proteins market covered in this report is segmented -

1) By Product: Antibodies, Cytokines, Immune Checkpoint Protein, Virus Antigens, Enzymes, Recombinant Regulatory Proteins, Hormones, Other Products
2) By Application: Drug And Discovery Development, Therapeutics, Research, Other Applications
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institute, Diagnostic Laboratories, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

"Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.